Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. Issue 11 (16th June 2011)

• Record Type: Journal Article
• Authors: Ricardo, Sara; Vieira, André Filipe; Gerhard, Renê; Leitão, Dina; Pinto, Regina; Cameselle-Teijeiro, Jorge F; Milanezi, Fernanda; Schmitt, Fernando; Paredes, Joana
• Is Part Of: Journal of clinical pathology. Volume 64:Issue 11(2011)
• Page Start: 937
• Page End: 946
• Publication Date: 2011-06-16
• Subjects: ALDH1 -- breast cancer -- breast cancer stem cells -- CD24 -- CD44 -- molecular subtypes -- tumour markers; Pathology -- Periodicals; Pathology, Molecular -- Periodicals; 616.0705
• DOI: 10.1136/jcp.2011.090456
• Languages: English
• ISSNs: 0021-9746

Abstract

Abstract : Background and Aim: The study of CD44/CD24 and ALDH1 expression is the most accurate method to identify cancer stem cells (CSC) from breast cancer populations. However, the overlap between CD44 + CD24 −/low and ALDH1 high CSC phenotypes in breast cancer seems to be very small, as well as their distribution among intrinsic breast cancer subtypes. Due to this discrepancy, it is imperative to improve the understanding of breast CSC marker distribution. Methods: 466 invasive breast carcinomas and eight breast cancer cell lines were analysed for the expression of CD44, CD24 and ALDH1, to evaluate their distribution among the distinct molecular subtypes. Results: Basal-like tumours (76.5%) contained the higher percentage of cells with the CSC phenotype CD44 + CD24 −/low (p<0.0001). From ALDH1-positive cases, 39.4% were also basal-like tumours (p<0.0001). The analysis of breast cancer cell lines indicated that luminal cell lines are mainly enriched in a CD44 −/low CD24 + cell population, basal/mesenchymal breast cancer cell lines are enriched in the CD44 + CD24 −/low phenotype, whereas the remaining basal/epithelial cell lines are mainly positive for both markers. ALDH1 activity was mainly found in HER-OE and basal/epithelial breast cancer cell. Conclusions: CD44 + CD24 −/low and ALDH1 + phenotypes seem to identify CSC with distinct levels of differentiation. It seems that the paramount method and biomarkers that identify breast CSC within the distinct molecular subtypes need to be better explored, because it is pivotal to translate the CSC concept to clinical practice. In the future, the recognition of reliable markers to distinguish the CSC pool in each molecular subtype will be decisive for the development of specific target therapies.